# US 2010/0304393 A1 · Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0304393 A1
- Document ID: US20100304393A1
- Status: Published application
- Kind: A1
- Application number: 12/801,248
- Filed: 2010-05-28
- Published: 2010-12-02
- Earliest claimed: 2009-05-28
- Assignees: Institut de Cardiologie de Montreal
- Inventors: Marie-Pierre Dubé; Hannah Beattie
- Web page: https://patentgrep.com/patent/US20100304393A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy.

## Claims

### Claim 1

A method of identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy, the method comprising:
testing the subject to check for a presence of a predetermined genetic variation, wherein the predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy; and
identifying the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation.

### Claim 2 (depends on 1)

A method in accordance with claim 1, wherein the predetermined genetic variation is located in the CYP4F2 gene.

### Claim 3 (depends on 2)

A method in accordance with claim 2, wherein the predetermined genetic variation is a predetermined single nucleotide polymorphism (SNP) in the CYP4F2 gene.

### Claim 4 (depends on 3)

A method in accordance with claim 3, wherein the predetermined SNP is rs2108622.

### Claim 5 (depends on 1)

A method in accordance with claim 1, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally above a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally above the patient-specific target therapeutic INR range.

### Claim 6 (depends on 1)

A method in accordance with claim 1, wherein the predetermined genetic variation is located in the NR1I2 gene.

### Claim 7 (depends on 6)

A method in accordance with claim 6, wherein the predetermined genetic variation is a predetermined single nucleotide polymorphism (SNP) in the NR1I2 gene.

### Claim 8 (depends on 7)

A method in accordance with claim 7, wherein the predetermined SNP is rs6772976.

### Claim 9 (depends on 8)

A method in accordance with claim 8, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally below a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally below the patient-specific target therapeutic INR range.

### Claim 10 (depends on 1)

A method in accordance with claim 1, wherein the subject is human.

### Claim 11 (depends on 1)

A method in accordance with claim 1, wherein the predetermined genetic variation is a predetermined single nucleotide polymorphism (SNP).

### Claim 12 (depends on 11)

A method in accordance with claim 11, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally below a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally below the patient-specific target therapeutic INR range.

### Claim 13 (depends on 11)

A method in accordance with claim 11, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally above a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally above the patient-specific target therapeutic INR range.

### Claim 14 (depends on 1)

A method in accordance with claim 1, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally outside a patient-specific target therapeutic INR range, presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally outside the patient-specific target therapeutic INR range, and wherein the patient-specific target therapeutic INR range is set to 2-3.

### Claim 15 (depends on 13)

A method in accordance with claim 13, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally outside a patient-specific target therapeutic INR range, presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally outside the patient-specific target therapeutic INR range, and wherein the patient-specific target therapeutic INR range is set to 2.5-3.5.

### Claim 16 (depends on 1)

A method in accordance with claim 1, wherein the predisposition to the abnormal INR fluctuation is during a post-stabilization period of the warfarin therapy.

### Claim 17 (depends on 1)

A method in accordance with claim 1, wherein the step of identifying the subject as having the predisposition to abnormal INR fluctuation during warfarin therapy includes performing a hybridization reaction followed by fluorescence in situ hybridization.

### Claim 18 (depends on 1)

A method in accordance with claim 1, wherein the step of identifying the subject as having the predisposition to abnormal INR fluctuation during warfarin therapy includes performing at least one of a DNA sequencing procedure, a PFGE analysis procedure, a Southern blot analysis procedure, a single stranded conformation analysis procedure, and a RNase protection assay procedure.

### Claim 19

A kit for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy, the kit comprising:
a test to check the subject for a presence of a predetermined genetic variation, wherein the predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy; and
an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy.

### Claim 20 (depends on 19)

A kit in accordance with claim 19, wherein the test is configured to check the subject for the predetermined genetic variation in the CYP4F2 gene.

### Claim 21 (depends on 21)

A kit in accordance with claim 21, wherein the test is configured to check the subject for the predetermined genetic variation in a predetermined single nucleotide polymorphism (SNP) in the CYP4F2 gene.

### Claim 22 (depends on 22)

A kit in accordance with claim 22, wherein the predetermined SNP is rs2108622.

### Claim 23 (depends on 22)

A kit in accordance with claim 22, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally above a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally above the patient-specific target therapeutic INR range.

### Claim 24 (depends on 22)

A kit in accordance with claim 22, wherein the test is configured to check the subject for the predetermined genetic variation in the NR1I2 gene.

### Claim 25 (depends on 24)

A kit in accordance with claim 24, wherein the test is configured to check the subject for the predetermined genetic variation in a predetermined single nucleotide polymorphism (SNP) in the NR1I2 gene.

### Claim 26 (depends on 25)

A kit in accordance with claim 25, wherein the predetermined SNP is rs6772976.

### Claim 27 (depends on 26)

A kit in accordance with claim 26, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally below a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally below the patient-specific target therapeutic INR range.

### Claim 28 (depends on 19)

A kit in accordance with claim 19, wherein the subject is human.

### Claim 29 (depends on 19)

A kit in accordance with claim 19, wherein the predetermined genetic variation is a predetermined single nucleotide polymorphism (SNP).

### Claim 30 (depends on 29)

A kit in accordance with claim 29, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally below a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally below the patient-specific target therapeutic INR range.

### Claim 31 (depends on 29)

A kit in accordance with claim 29, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally above a patient-specific target therapeutic INR range, and presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally above the patient-specific target therapeutic INR range.

### Claim 32 (depends on 19)

A kit in accordance with claim 19, wherein the patient-specific target therapeutic INR range is set to 2-3.

### Claim 33 (depends on 19)

A kit in accordance with claim 19, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally outside a patient-specific target therapeutic INR range, presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally outside the patient-specific target therapeutic INR range, and wherein the patient-specific target therapeutic INR range is set to 2-3.

### Claim 34 (depends on 19)

A kit in accordance with claim 19, wherein the predetermined SNP is correlated with the abnormal INR fluctuation being generally outside a patient-specific target therapeutic INR range, presence of the predetermined SNP identifies the subject as having a predisposition to the abnormal INR fluctuation being generally outside the patient-specific target therapeutic INR range, and wherein the patient-specific target therapeutic INR range is set to 2.5-3.5.

### Claim 35 (depends on 19)

A kit in accordance with claim 19, wherein the test to check the subject for the presence of the predetermined genetic variation is conducted during a post-stabilization period of the warfarin therapy.

### Claim 36 (depends on 19)

A kit in accordance with claim 19, wherein the test to check the subject for the presence of the predetermined genetic variation includes performing a hybridization reaction followed by fluorescence in situ hybridization.

### Claim 37 (depends on 19)

A kit in accordance with claim 19, wherein the test to check the subject for the presence of the predetermined genetic variation includes performing at least one of a DNA sequencing procedure, a PFGE analysis procedure, a Southern blot analysis procedure, a single stranded conformation analysis procedure, and a RNase protection assay procedure.
